Inhibition of the activity or function of numerous targets, including vasopressin receptors, calcium-sensing receptors, CFTRs, the cell cycle, and mTOR have been proposed for ADPKD treatment [8,13,14,15,16,17,18,19]. Here, MTOR is linked to autosomal dominant polycystic kidney disease.